Clinical Trial Update: A Open-label Study of Ultra-High Dose Dexamethasone for Relapsed Multiple Myeloma [Phase 2]

View source ↗

Summary

The open-label Phase 2 trial of ultra-high-dose dexamethasone for relapsed multiple myeloma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)

Snippet

Sponsor: Boston Medical Center | Conditions: Multiple Myeloma | Phase 2 | Status: WITHDRAWN